DOI: 10.4244/EIJV9I7A148

Revisiting: “Comparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patients”

Yao-Jun Zhang1,2, MD, PhD; Hector M. Garcia-Garcia2, MD, PhD; Vasim Farooq2, MBChB, MRCP; Christos V. Bourantas2, MD, PhD; Patrick W. Serruys2, MD, PhD; Shao-Liang Chen1*, MD, PhD

Recently, we have published the manuscript entitled “Comparison of intravascular ultrasound versus angiography-guided drug-eluting stent (DES) implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patients”. Two additional important studies (namely, the ADAPT-DES and the RESET), comparing IVUS- and angiography-guided DES implantation have recently been reported1,2. In addition, the two-year clinical follow-up of the randomised AVIO trial was published recently3. Therefore, our meta-analysis needs to be updated.

The ADAPT-DES (Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents) trial was a prospective multicentre registry study that enrolled approximately 11,000 patients1. The outcomes, after IVUS-guided percutaneous coronary intervention (PCI), were compared to the non-IVUS-guided PCI group in 8,575 patients. A significant reduction in the primary endpoint of definite/probable stent thrombosis was evident in patients who underwent PCI under IVUS guidance (vs. angiography guidance) at one-year follow-up (0.52% vs. 1.04%, p=0.011). In the pre-specified long lesion subset of the RESET (Real Safety and Efficacy of a 3-month Dual Antiplatelet Therapy Following Zotarolimus-eluting Stents Implantation) trial2, 543 patients were enrolled and randomised to either the IVUS- or angiography-guided PCI group. IVUS-guided PCI was related to a significantly lower risk of major adverse cardiac events (MACE) at one-year follow-up compared to angiographic guidance (4.0% vs. 8.1%, p=0.048). In the AVIO trial, no statistical differences were observed in MACE (16.9% vs. 23.2%) or target lesion revascularisation (TLR, 9.2% vs. 11.9%) between the IVUS- and angiography-guided groups3.

Based on the available data, the currently updated meta-analysis includes 14 studies involving 29,029 patients (Figure 1)1-4. The revisited meta-analysis not only confirms our previous findings that IVUS guidance was associated with reductions in death (hazard ratio [HR]: 0.66, 95% confidence interval [CI]: 0.55-0.78, p<0.001), stent thrombosis (HR: 0.57, 95% CI: 0.44-0.73, p<0.001), myocardial infarction (MI) (HR: 0.74, 95% CI: 0.62-0.90, p=0.002) and MACE (HR: 0.86, 95% CI: 0.77-0.95, p=0.003), but also shows the beneficial effect of IVUS guidance in reducing TLR (HR: 0.82, 95% CI: 0.68-0.97, p=0.02). Since the present meta-analysis included mostly observational studies, no significant publication bias was identified using Egger’s linear regression test (p=0.50 for death; p=0.85 for ST; p=0.69 for MI, p=0.33 for MACE, p=0.67 for TLR). Although the present meta-analysis supports and strengthens the previously reported results, appropriately powered randomised trials are necessary to provide robust evidence and verify the practical value of IVUS-guided DES implantation.

Figure 1. Hazard ratios and forest plots for (A) death, (B) stent thrombosis, (C) myocardial infarction, and (D) target lesion revascularisation associated with IVUS- versus non-IVUS-guided drug-eluting stent implantation. CI: confidence interval; HR: hazard ratio; IVUS: intravascular ultrasound

Conflict of interest statement

The authors have no conflicts of interest to declare.

Volume 9 Number 7
Nov 29, 2013
Volume 9 Number 7
View full issue


Key metrics

On the same subject

Editorial

10.4244/EIJ-E-23-00052 Mar 18, 2024
Comparative preclinical assessment of drug-coated balloons: a blessing and a curse for clinical translation
Joner M and Wild L
free

Debate

10.4244/EIJ-E-24-00005 Mar 18, 2024
Ischaemic and viability testing for guiding PCI are overrated: pros and cons
McEntegart M et al
free

Original Research

10.4244/EIJ-D-23-00783 Mar 18, 2024
Redo-TAVI with the ACURATE neo2 and Prime XL for balloon-expandable transcatheter heart valve failure
Meier D et al
Trending articles
281.53

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved